TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27895003
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein supplementation (1.2 g/kg IBW per day)
Study: 27895003
Drug: Standard protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protein supplementation (0.8 g/kg IBW per day)
Study: 27895279
Drug: Immunoglobulin G
Normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin G (IgG) responses to malaria
Study: 27896545
Drug: Pasireotide long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide long-acting release 40 mg administered intramuscularly every 28 days
Study: 27896822
Drug: Simeprevir 150
Normalized name: simeprevir 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir 150 mg once-daily plus Sofosbuvir 400 mg once-daily for 12 weeks
Study: 27896822
Drug: Simeprevir plus
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simeprevir plus Sofosbuvir treatment
Study: 27900346
Drug: ZFN-mediated CCR5
Normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZFN-mediated CCR5 disruption in HSPC; specific dosage and duration not mentioned.
Study: 27900346
Drug: Allogeneic stem
Normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic stem cell transplantation with naturally occurring homozygous deletion of CCR5 in donor HSPC; specific dosage and duration not mentioned.
Study: 27900579
Drug: AhR agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: AhR agonist treatment
Study: 27903416
Drug: JE-CV (live
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE-CV (live attenuated Japanese encephalitis vaccine) administered as primary vaccination (Group 1)
Study: 27903416
Drug: JE-CV (live
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE-CV (live attenuated Japanese encephalitis vaccine) administered as booster vaccination (Group 2)
Study: 27903616
Drug: hs-TnI cutoff
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-TnI cutoff of 3 ng/L with low risk ECG
Study: 27904903
Drug: eGFR <45
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR <45 ml/min/1.73 m²
Study: 27904904
Drug: N8-GP for
Normalized name: N8-GP
DrugBank: Turoctocog alfa pegol (DB14738)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: N8-GP for on-demand treatment (20-75 IU/kg)
Study: 27906044
Drug: Dense breasts
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dense breasts (>50% density) with positive margin, no adjuvant radiotherapy, and no adjuvant chemotherapy
Study: 27908594
Drug: Rucaparib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib (600 mg twice per day for continuous 28 day cycles)
Study: 27908843
Drug: Telemedically-delegated medication
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedically-delegated medication by paramedics (study group)
Study: 27911128
Drug: Docetaxel in
Normalized name: docetaxel Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel in combination with oxaliplatin and S-1 (DOS2w)
Study: 27911128
Drug: Docetaxel in
Normalized name: docetaxel Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel in combination with oxaliplatin and S-1 (DOS3w)
Study: 27911591
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone (GnRH) analog treatment
Study: 27912069
Drug: Inactivated quadrivalent
Normalized name: influenza virus vaccine, inactivated quadrivalent intramuscular suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated quadrivalent influenza vaccine (Fluarix™ Tetra)
Study: 27912784
Drug: Liraglutide (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.2 mg/day) added to metformin (1500-3000 mg/day)
Study: 27913777
Drug: Ultrasound-facilitated, catheter-directed,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis
Study: 27913881
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus oral leucovorin (S-1/LV)
Study: 27914133
Drug: Lobeglitazone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobeglitazone 0.5 mg once daily for 24 weeks
Study: 27914971
Drug: Ofatumumab 300
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab 300 mg during week 1 followed by 1000 mg during weeks 2-4 (Group A)
Study: 27914971
Drug: Ofatumumab 300
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab 300 mg during week 1 and 2000 mg during weeks 2-5 (Group B)
Study: 27914971
Drug: Ofatumumab 300
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab 300 mg during week 1 and 2000 mg during weeks 2-5 (Cycle 2 for responders)
Study: 27915457
Drug: Pharmacist-led intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led intervention using the RASP list and medication review
Study: 27918881
Drug: QUIT4EVER (mobile
Approvals — FDA: no, EMA: no, PMDA: no
Description: QUIT4EVER (mobile contingency management smoking cessation counseling and medications + Stay Quit Coach)
Study: 29143565
Drug: Darunavir 800
Normalized name: darunavir 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir 800 mg once daily (QD)
Study: 27919899
Drug: Darunavir 600
Normalized name: darunavir 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir 600 mg twice daily (BID)
Study: 27919899
Drug: Three-direct-acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-direct-acting antiviral (3D) regimen with ribavirin (RBV)
Study: 27921340
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy (speech exposure session)
Study: 27923043
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg daily until progression
Study: 27923043
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg daily and intravenous vinorelbine 25 mg/m2 weekly after progression
Study: 27923359
Drug: Sertraline (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (doses ranged from 12.5 to 150 mg/day, mostly 25 and 50 mg/day)
Study: 27926979
Drug: Erythropoiesis-stimulating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis-stimulating agents (ESAs), median duration of 27.5 months (range 0-77 months)
Study: 27927586
Drug: RBAC500 (rituximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBAC500 (rituximab 375 mg/m2, bendamustine, low-dose cytarabine)
Study: 27927635
Drug: Iodine intake
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine intake of 200-249 μg/d for children aged 7-10 y
Study: 27927635
Drug: Iodine intake
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine intake of 250-299 μg/d for children aged 11-14 y
Study: 27927635
Drug: Iodine intake
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine intake ≥150 μg/d
Study: 27927635
Drug: Iodine intake
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine intake ≥250 μg/d for children aged 7-10 y
Study: 27927635
Drug: Iodine intake
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine intake ≥300 μg/d for children aged 11-14 y
Study: 27927635
Drug: Iodine intake
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine intake of 150-249 μg/d for children aged 7-10 y
Study: 27927635
Drug: Iodine intake
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine intake of 150-299 μg/d for children aged 11-14 y
Study: 27927766
Drug: Rebastinib (DCC-2036)
Normalized name: Rebastinib
DrugBank: Rebastinib (DB13005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebastinib (DCC-2036) administered at doses from 57 mg to 1200 mg daily (powder-in-capsule) and 100 mg to 400 mg daily (tablet preparations). Maximum tolerated dose was 150 mg tablets administered twice daily.
Study: 27928641
Drug: Severe dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe dental conditions (poor oral hygiene)
Study: 27928738
Drug: Clarithromycin 1000
Normalized name: clarithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 1000 mg
Study: 27930357
Drug: High adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High adenosine dose (200 μg/kg per minute)
Study: 27930357
Drug: Standard adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard adenosine dose (140 μg/kg per minute)
Study: 27931243
Drug: Pacritinib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacritinib 400 mg QD
Study: 27931243
Drug: Pacritinib 100
Normalized name: pacritinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacritinib 100 to 600 mg QD
Study: 27931243
Drug: Pacritinib 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacritinib 500 mg QD
Study: 27932068
Drug: Rovalpituzumab tesirine
Normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovalpituzumab tesirine 0.2 mg/kg every 3 weeks
Study: 27932068
Drug: Rovalpituzumab tesirine
Normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovalpituzumab tesirine 0.4 mg/kg every 3 weeks
Study: 27932068
Drug: Rovalpituzumab tesirine
Normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovalpituzumab tesirine 0.3 mg/kg every 6 weeks
Study: 27932068
Drug: Rovalpituzumab tesirine
Normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovalpituzumab tesirine 0.4 mg/kg every 6 weeks
Study: 27932068
Drug: Rovalpituzumab tesirine
Normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovalpituzumab tesirine 0.8 mg/kg every 3 weeks
Study: 27932068
Drug: Rovalpituzumab tesirine
Normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovalpituzumab tesirine (various doses)
Study: 27932629
Drug: London Chest
Normalized name: London planetree
Approvals — FDA: no, EMA: no, PMDA: no
Description: London Chest Activities of Daily Living Scale
Study: 27933199
Drug: RCI 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCI 40 U daily
Study: 27933199
Drug: RCI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCI treatment
Study: 27933679
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation for 2 weeks
Study: 27935524
Drug: Low urinary
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low urinary potassium excretion (UKV <55 mmol/24 h for women; <65 mmol/24 h for men)
Study: 27935524
Drug: Mean urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean urinary potassium excretion (UKV) in RTRs
Study: 27935737
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) for 30 minutes, three times weekly for 4 weeks
Study: 27935867
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of OTX015 and everolimus
Study: 27935867
Drug: OTX015 as
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTX015 as single agent
Study: 27935867
Drug: Combination with
Normalized name: Iron in combination with folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination with everolimus
Study: 27938896
Drug: Home administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home administration of intranasal LAIV by parents
Study: 27938911
Drug: Propofol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (3 mg/kg) infusion for 10 minutes
Study: 27942917
Drug: LJM716 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: LJM716 (40 mg/kg, intravenously, once weekly in 28-day cycles)
Study: 27943107
Drug: IDegLira once
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IDegLira once daily
Study: 27943107
Drug: Unchanged GLP-1RA
Normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Unchanged GLP-1RA therapy
Study: 27955684
Drug: Pertuzumab (840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertuzumab (840 mg loading, 420 mg maintenance doses) and Trastuzumab (8 mg/kg loading, 6 mg/kg maintenance doses), followed by Vinorelbine (25 mg/m2)
Study: 27956157
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg once daily until progression or unacceptable toxicity
Study: 27956421
Drug: Miltefosine (Impavido)
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miltefosine (Impavido) at a nominal dose of 2.5 mg/kg/day for 28 days
Study: 27959731
Drug: Decitabine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine (20 mg/m²/day for 10 consecutive days in monthly cycles)
Study: 27964869
Drug: Voluntary methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voluntary methadone treatment in VTCs
Study: 27964869
Drug: Compulsory drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compulsory drug detention centres (CDDCs)
Study: 27965789
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 0.5% ropivacaine
Study: 27965789
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml 0.33% ropivacaine
Study: 27965789
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml 0.25% ropivacaine
Study: 27965798
Drug: Probiotics administered
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics administered to mechanically ventilated critically ill patients
Study: 27965808
Drug: Multi-component physiotherapist-led
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component physiotherapist-led intervention including a 40-min education module, guided goal-setting, action planning, wristband activity tracker, and weekly follow-up phone calls.
Study: 27965809
Drug: Glycerin suppository
Normalized name: Leader Pediatric Glycerin Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerin suppository (250 mg)
Study: 27965809
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 mg glycerin suppository placed in the diaper)
Study: 27965816
Drug: Data collection
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data collection on clinical history, diagnostic path, treatment, and urine culture
Study: 27965841
Drug: Behavioral activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral activation (BA) group therapy
Study: 27965866
Drug: Natural progesterone
Normalized name: NATURAL PROGESTERONE CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural progesterone (Prometrium, 200 mg) vaginally every night from gestational week 16 to 36
Study: 27965885
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (two 30-45 min sessions per week for three consecutive weeks, in addition to care as usual)
Study: 27966809
Drug: Carboxypeptidase G2
Normalized name: Carboxypeptidase G2
DrugBank: Glucarpidase (DB08898)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Carboxypeptidase G2 (CPDG) administered to 47 children
Study: 27966809
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (5 g/m2)
Study: 27967215
Drug: Intramuscular triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular triamcinolone acetonide (TA)
Study: 27977390
Drug: Population pharmacokinetics
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Population pharmacokinetics models
Study: 27978569
Drug: Low-vision devices
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-vision devices with therapy
Study: 27978569
Drug: Low-vision devices
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-vision devices without therapy
Study: 27979025
Drug: Atopy patch
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atopy patch tests (APTs) with locally lyophilized food allergens
Study: 27979025
Drug: Atopy patch
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atopy patch tests (APTs) for D. farinae, D. pteronyssinus, and American cockroach
Study: 27980771
Drug: Neurobiologically based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurobiologically based five-day treatment for anorexia nervosa
Study: 27980787
Drug: Group training
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group training program based on cognitive-behavioral principles and skills from Dialectical Behavior Therapy (DBT)
Study: 27980877
Drug: Suprachoroidal injection
Normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprachoroidal injection of 4-mg triamcinolone acetonide (TA) in 100 μL
Study: 27986651
Drug: Alirocumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (150 mg, 5 doses, 2 weeks apart)
Study: 27988497
Drug: Moderately reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately reduced kidney function (eGFR 30 to 60 mL/min per 1.73 m²)
Study: 27988497
Drug: Normal kidney
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal kidney function (eGFR >60 mL/min per 1.73 m²)
Study: 27989789
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (programmed with 1 or 2 therapy zones)
Study: 27989886
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of rosuvastatin daily for 8 to 12 weeks
Study: 27992451
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg BID with Vinorelbine 30 mg/m2 IV days 1,8 every 21 days
Study: 27993904
Drug: CPET after
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPET after treatment of iliofemoral occlusive arterial disease
Study: 27993904
Drug: CPET before
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPET before treatment of iliofemoral occlusive arterial disease
Study: 27993926
Drug: HOMA-IR (HOMA-insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOMA-IR (HOMA-insulin resistance)
Study: 27996967
Drug: AdhAQP1 administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AdhAQP1 administration
Study: 27998970
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 on day 1, Cisplatin 50 mg/m2 on day 2, Veliparib escalating doses from 50 to 400 mg orally two times daily on days 1-7
Study: 27999035
Drug: Intravenous intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous intermittent dosing (ID) of vancomycin
Study: 27999035
Drug: Continuous dosing
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous dosing (CD) of vancomycin
Study: 27999035
Drug: Vancomycin therapy
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin therapy (general)
Study: 27999038
Drug: ABX464 (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 (50, 100, 150 or 200 mg)
Study: 27999040
Drug: Cefazolin administered
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin administered before surgical incision, before cessation of CPB, and after surgery.
Study: 27999040
Drug: Cefazolin dosing
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin dosing regimen with an additional bolus dose at the start of CPB.
Study: 27999040
Drug: Cefazolin dosing
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin dosing regimen during prolonged surgery with preserved renal function.
Study: 27999607
Drug: Loquat Leaf
Normalized name: Belladonna Leaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loquat Leaf Extract (500 mg, 50.94 mg of Ursolic Acid)
Study: 27999670
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy group treatment
Study: 28000190
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation (FMT) combined with soluble dietary fiber (pectin, 8 g/d) and probiotics (bifid triple viable capsules, twice per day) for 4 weeks after initial treatment with vancomycin 500 mg orally twice per day for 3 days.
Study: 28003133
Drug: Placebo pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pulsed shortwave therapy (control group), 30 minutes per session.
Study: 28003301
Drug: Sublingual video-microscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual video-microscopy
Study: 28005959
Drug: P-TIV (Proteosome-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-TIV (Proteosome-adjuvanted trivalent inactivated influenza vaccine) - 1 x 30 μg, 2 x 30 μg, 2 x 15 μg
Study: 28005959
Drug: P-TIV (Proteosome-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-TIV (Proteosome-adjuvanted trivalent inactivated influenza vaccine)
Study: 28005959
Drug: P-TIV (Proteosome-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-TIV (Proteosome-adjuvanted trivalent inactivated influenza vaccine) - 2 doses vs 1 dose